Management of female sexual dysfunction in postmenopausal women by testosterone administration: Safety issues and controversies

Journal of Sexual Medicine

Volumn 4, Issue 4 I, 2007, Pages 859-866

  Braunstein, Glenn D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Cardiovascular disease; Endometrial cancer; Hirsutism; Menopause; Testosterone

Indexed keywords

ANDROGEN; BLOOD CLOTTING FACTOR; ESTRATEST; ESTROGEN; GESTAGEN; LIPID; METHYLTESTOSTERONE; PLACEBO; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ACNE; AGGRESSIVENESS; ANDROGEN THERAPY; BEHAVIOR DISORDER; BIBLIOGRAPHIC DATABASE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; BLOOD VISCOSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM HYPERPLASIA; FEMALE SEXUAL DYSFUNCTION; HEART DEATH; HEART INFARCTION; HIRSUTISM; HOSTILITY; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN RESISTANCE; LIBIDO DISORDER; LIPID BLOOD LEVEL; LIVER ADENOMA; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL LITERATURE; MONOTHERAPY; NONHUMAN; PELIOSIS HEPATIS; POLYCYTHEMIA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; VIRILIZATION;

EID: 34447530314     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00516.x     Document Type: Review

References (52)

1. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2007; 4 (suppl. 3): 227-34.
2. Schwenkhagen A. Hormonal changes in menopause and implications on sexual health. J Sex Med 2007; 4 (suppl. 3): 220-6.
3. Advisory Committee for Reproductive Health Drugs. Available at: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4082T1.htm (accessed December 2, 2004).
4. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: A review of the safety literature, 1941-1996. Clin Ther 1997; 19: 383-404; discussion 367-8.
5. Barrett-Connor E, Timmons C, Young R, Wiita B. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Womens Health 1996; 5: 593-602.
6. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341-52.
7. Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: Evidence from clinical studies. Int J Fertil Womens Med 1998; 43: 98-103.
8. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with oestradiol-testosterone implants: Clinical, lipid and hormonal results. Maturitas 1984; 6: 351-8.
9. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-8.
10. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005; 165: 1582-9.
11. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005; 105 (5 part 1): 944-52.
12. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226-33.
13. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, Shoukri K, Smith J. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996; 81: 37-43.
14. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999; 44: 1012-20.
15. Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther 1997; 19: 1070-84.
16. Cardozo L, Gibb DM, Tuck SM, Thom MH, Studd JW, Cooper DJ. The effects of subcutaneous hormone implants during climacteric. Maturitas 1984; 5: 177-84.
17. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227-36.
18. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003; 10: 390-8.
19. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991; 77: 595-8.
20. Gelfand M. Elevated serum testosterone, hirsuitsm, and virilism associated with combined androgen-estrogen hormone replacement therapy [letter]. Obstet Gynecol 1991; 78 (part 1): 474.
21. Meyer WJ 3rd, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: A longitudinal study. Arch Sex Behav 1986; 15: 121-38.
22. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
23. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183-217.
24. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995; 311: 1193-6.
25. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-42.
26. Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC, Lloyd-Jones D, Sowers MF, Torrens JI. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242-9.
27. Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil Steril 2004; 82: 273-89.
28. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58: 562-71.
29. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86: 158-61.
30. Basaria S, Dobs AS. Safety and adverse effects of androgens: How to counsel patients. Mayo Clin Proc 2004; 79 (4 suppl.): S25-32.
31. Buckler HM, McElhone K, Durrington PN, Mackness MI, Ludlam CA, Wu FC. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) 1998; 49: 173-8.
32. Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88: 5723-9.
33. Schlatterer K, Yassouridis A, von Werder K, Poland D, Kemper J, Stalla GK. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Arch Sex Behav 1998; 27: 475-92.
34. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 1998; 83: 4420-5.
35. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79: 265-71.
36. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006; 13: 387-96.
37. Herbst KL, Calof OM, Hsia SH, Sinha-Hikim I, Woodhouse LJ, Buchanan TA, Bhasin S. Effects of transdermal testosterone administration on insulin sensitivity, fat mass and distribution, and markers of inflammation and thrombolysis in human immunodeficiency virus-infected women with mild to moderate weight loss. Fertil Steril 2006; 85: 1794-802.
38. Pike MC, Ross RK. Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer. Steroids 2000; 65: 659-64.
39. Tuckerman EM, Okon MA, Li T, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril 2000; 74: 771-9.
40. Boman K, Strang P, Backstrom T, Stendahl U. The influence of progesterone and androgens on the growth of endometrial carcinoma. Cancer 1993; 71: 3565-9.
41. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 study. Menopause 2006; 13: 770-9.
42. Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 1986; 62: 16-21.
43. Somboonporn W, Davis SR. Testosterone effects on the breast: Implications for testosterone therapy for women. Endocr Rev 2004; 25: 374-88.
44. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10: 292-8.
45. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006; 166: 1483-9.
46. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986; 54: 825-32.
47. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832-8.
48. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11: 531-5.
49. Braunstein GD. Comment on "Combined estrogen and androgen therapies increase risk of breast cancer."First to Know (http://www.menopause.org/news.html). September 12, 2006, pp. 4-6.
50. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: A comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993; 170: 37-43.
51. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet 1977; 2: 262-3.
52. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: A double-blind, cross-over study. Psychoneuroendocrinology 1985; 10: 325-35.